Cme (CME) EBITDA (2009 - 2026)

Cme (CME) has 18 years of EBITDA data on file, last reported at $1.3 billion in Q1 2026.

• Quarterly EBITDA rose 17.76% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 billion (up 8.36% YoY) and the FY2025 annual result came in at $4.2 billion, up 7.58% from the prior year.
• EBITDA climbed to $1.3 billion in Q1 2026 per CME's latest filing, from $1.0 billion in the prior quarter.
• Across five years, EBITDA topped out at $1.3 billion in Q1 2026 and bottomed at $668.3 million in Q4 2022.
• The 5-year median for EBITDA is $947.1 million (2024), against an average of $959.6 million.
• The widest annual swing landed in 2023, when EBITDA climbed 29.16%; it then dropped 5.07% in 2025.
• Tracing CME's EBITDA over 5 years: stood at $668.3 million in 2022, then increased by 29.16% to $863.2 million in 2023, then gained by 9.72% to $947.1 million in 2024, then advanced by 7.65% to $1.0 billion in 2025, then jumped by 31.12% to $1.3 billion in 2026.
• Per Business Quant, the three latest CME EBITDA figures stand at $1.3 billion (Q1 2026), $1.0 billion (Q4 2025), and $999.0 million (Q3 2025).

Peer Comparison